Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Scarce evidence exists on the demands needed to attain the highest positions during Grand Tours (Giro d'Italia, Tour de France, Vuelta a España). Using power output (PO) and heart rate (HR) data, we aimed to compare the racing demands of successful (at least top-5) and less successful (at least top-15) cyclists during Grand Tours. We identified Grand Tours in which we could compare cyclists who had attained a top-5 position (Top) with riders who also competed for the General Classification in the same race but attained a worse position (Non-Top, at least top 15). Different race-derived measures of physical demands (e.g., PO, kJ spent, training stress score, durability and repeatability measures, time in different PO/HR zones) were analyzed. Data from 9 Grand Tours, including 9 Top (average position 3rd, range 1st-5th) and 9 Non-Top cyclists (average position 9th, range 4th-12th) were available. Despite significant between-group differences in finishing time (86.2 ± 6.3 vs. 86.3 ± 6.3 h, p < 0.001), no differences were found for any of the analyzed outcomes, except for a slightly higher proportion of time spent at low PO levels (zone 1 (≤ 55% of functional threshold power)) in Top compared to Non-Top cyclists (60.9% ± 1.8% vs. 58.4% ± 2.5%, respectively, p = 0.011). In summary, achieving a top position during a Grand Tour does not necessarily imply overall higher physical demands compared to those cases in which cyclists attain a slightly lower position, which suggests that other factors (e.g., individual or team tactics) or metrics might have a greater influence.

Download full-text PDF

Source
http://dx.doi.org/10.1111/sms.70074DOI Listing

Publication Analysis

Top Keywords

grand tours
20
power output
8
output heart
8
racing demands
8
cyclists grand
8
average position
8
grand
5
tours
5
reach podium?
4
podium? power
4

Similar Publications

Accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non-curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therapy, while some studies advocate for combination therapy with either ruxolitinib (RUXO) or venetoclax (VEN). To assess the relationship between treatment modalities and outcome, herein, we report a multicentric cohort of 149 patients (median age, 75 years) with AP/BP MPN not eligible for intensive therapy and/or allogeneic hematopoietic cell transplantation who received azacitidine (AZA) alone ( = 60) or in combination ( = 89; VEN [ = 51], RUXO [ = 27], or both [ = 9], isocitrate dehydrogenase inhibitors [ = 2]) between January 2019 and October 2023. With a median follow-up of 15 months, the median overall survival of the full cohort was 8.

View Article and Find Full Text PDF

Spinal cord malformations's epidemiology in French children: National cross sectional study based on medico-administrative database.

Neurochirurgie

September 2025

Department of Pediatric Orthopedic Surgery, Regional University Hospital Center of Tours, France; Regional Epidemiology Unit Centre-Val de Loire, Regional University Hospital Center of Tours, France; Reference Center for Rare Diseases, Chiari and Vertebral and Spinal Cord Malformations (C-MAVEM) of

Objective: Epidemiological data on rare spinal cord malformations in children are lacking in France. Using the national hospital discharge database (PMSI), we studied the care trajectories and estimated the morbidity and mortality burden of these conditions.

Study Design: We conducted a nationwide historical cohort study from 2010 to 2020, including children diagnosed with rare spinal cord diseases within the scope of the C-MAVEM network.

View Article and Find Full Text PDF

Introduction: Preterm infants are at risk of developmental impairment, especially those born before 33 weeks gestational age. Many studies have shown a positive impact of early interventions on medical outcomes during hospitalisation, long-term cognitive development and parental anxiety. Infant Behavioral Assessment and Intervention Program (IBAIP) has shown positive effects on cognitive development but also on motor impairment in a Dutch cohort.

View Article and Find Full Text PDF

Objective: Advanced or recurrent endometrial carcinoma (EC) represents a significant clinical challenge. This study aimed to evaluate patient (age and comorbidities) and disease (histological subtypes and stages) characteristics, treatment patterns and survival outcomes in a real-world French healthcare setting.

Methods And Analysis: In this national, multi-centre, retrospective observational cohort study, 200 patients with advanced or recurrent EC receiving first- or second-line chemotherapy during the year 2019 were analysed.

View Article and Find Full Text PDF

Introduction: Discrepancies in factor IX activity (FIX:C) measurements between one-stage clotting assays (OSAs) have been observed following infusion with recombinant factor IX extended half-life concentrates (EHL-rFIX) in the treatment of haemophilia B. These variations, primarily due to differences in activated partial thromboplastin time (APTT) reagents, complicate clinical decision-making.

Objectives: The aim of this study was to evaluate whether drug-specific calibrations for albumin-fused recombinant FIX (rFIX-FP) and Fc-fused recombinant FIX (rFIX-Fc) could reduce inter-reagent discrepancies.

View Article and Find Full Text PDF